NASDAQ:NVCR NovoCure (NVCR) Stock Price, News & Analysis $17.73 -0.02 (-0.11%) As of 12:36 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NovoCure Stock (NASDAQ:NVCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NovoCure alerts:Sign Up Key Stats Today's Range$17.33▼$17.8050-Day Range$10.35▼$18.3152-Week Range$9.82▼$20.06Volume297,528 shsAverage Volume1.79 million shsMarket Capitalization$2.05 billionP/E RatioN/ADividend YieldN/APrice Target$27.29Consensus RatingHold Company Overview NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies. Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire. The company entered the public markets with a Nasdaq IPO in December 2015, expanding its ability to fund clinical research and commercial deployment of its TTFields technology. Its flagship device, Optune, received regulatory approvals for recurrent and newly diagnosed glioblastoma multiforme in the U.S., Europe and other jurisdictions. Optune uses a portable electric field generator and transducer arrays worn on the scalp, representing a paradigm shift in the management of brain tumors. In addition to GBM, NovoCure is actively conducting clinical trials in pancreatic, ovarian, lung and liver cancers, as well as exploring applications in mesothelioma through its Optune Lua device. NovoCure markets its products across North America, Europe and the Asia-Pacific region, emphasizing patient access programs and physician engagement to drive adoption. The leadership team is spearheaded by founder and Chief Technology Officer Yoram Palti, whose foundational research underpins the TTFields platform, supported by a seasoned executive cadre overseeing global operations, regulatory affairs and clinical development.AI Generated. May Contain Errors. Read More NovoCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreNVCR MarketRank™: NovoCure scored higher than 66% of companies evaluated by MarketBeat, and ranked 284th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingNovoCure has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialNovoCure has a consensus price target of $27.29, representing about 53.9% upside from its current price of $17.72.Amount of Analyst CoverageNovoCure has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NovoCure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NovoCure are expected to grow in the coming year, from ($1.55) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -11.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -11.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NovoCure's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.37% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 4.07.Change versus previous monthShort interest in NovoCure has recently decreased by 19.99%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.09 News SentimentNovoCure has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NovoCure this week, compared to 4 articles on an average week.Search Interest10 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,860,116.00 in company stock.Percentage Held by Insiders5.52% of the stock of NovoCure is held by insiders.Percentage Held by Institutions84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NovoCure's insider trading history. Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVCR Stock News HeadlinesNovoCure (NASDAQ:NVCR) Stock Passes Above 50-Day Moving Average - Should You Sell?May 20 at 4:17 AM | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Hold" by BrokeragesMay 20 at 2:35 AM | americanbankingnews.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 21 at 1:00 AM | Paradigm Press (Ad)Stocks with rising relative price strength: NovocureMay 4, 2026 | msn.comNovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 2, 2026 | finance.yahoo.comNovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer YetMay 1, 2026 | seekingalpha.comNovoCure: Q1 Earnings SnapshotMay 1, 2026 | chron.comNovocure jumps after raising FY26 sales outlook, Q1 revenue beatMay 1, 2026 | seekingalpha.comSee More Headlines NVCR Stock Analysis - Frequently Asked Questions How have NVCR shares performed this year? NovoCure's stock was trading at $12.93 at the beginning of 2026. Since then, NVCR stock has increased by 37.1% and is now trading at $17.7240. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) issued its earnings results on Thursday, April, 30th. The medical equipment provider reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.11. The company's revenue for the quarter was up 12.3% on a year-over-year basis. Read the conference call transcript. When did NovoCure IPO? NovoCure (NVCR) raised $206 million in an initial public offering on Friday, October 2nd 2015. The company issued 7,500,000 shares at a price of $26.00-$29.00 per share. Who are NovoCure's major shareholders? NovoCure's top institutional shareholders include Quantinno Capital Management LP (2.15%), Renaissance Technologies LLC (1.34%), SG Americas Securities LLC (1.09%) and Dimensional Fund Advisors LP (0.83%). Insiders that own company stock include Frank X Leonard, Ashley Cordova, William F Doyle, Uri Weinberg, Wilhelmus Cm Groenhuysen, Michal Nath Puri, Christoph Brackmann, W Anthony Vernon, Pritesh Shah and Mukund Paravasthu. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovoCure investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD) and Intel (INTC). Company Calendar Last Earnings4/30/2026Today5/21/2026Next Earnings (Estimated)7/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, NVCR's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:NVCR CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,605Year Founded2000Price Target and Rating Average Price Target for NovoCure$27.29 High Price Target$49.00 Low Price Target$17.00 Potential Upside/Downside+54.3%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$136.23 million Net Margins-25.66% Pretax Margin-25.98% Return on Equity-50.82% Return on Assets-16.48% Debt Debt-to-Equity Ratio0.71 Current Ratio2.90 Quick Ratio2.70 Sales & Book Value Annual Sales$655.35 million Price / Sales3.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.86 per share Price / Book6.18Miscellaneous Outstanding Shares115,820,000Free Float109,428,000Market Cap$2.05 billion OptionableOptionable Beta0.90 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:NVCR) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
